- Home
- WDI vs SPRY Comparison
WDI vs SPRY Comparison
Compare WDI & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WDI | SPRY |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 703.9M | 788.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | WDI | SPRY |
|---|---|---|
| Price | $13.40 | $9.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 172.8K | ★ 1.8M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 11.80% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | N/A | $87.40 |
| Revenue Next Year | N/A | $81.64 |
| P/E Ratio | $11.99 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.91 | $6.66 |
| 52 Week High | $15.28 | $18.63 |
Technical Indicators
Market Signals| Indicator | WDI | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 40.24 | 57.15 |
| Support Level | $13.25 | $7.82 |
| Resistance Level | $13.70 | $9.51 |
| Average True Range (ATR) | 0.19 | 0.60 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 23.24 | 71.67 |
Price Performance
Historical ComparisonAbout WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income. As a secondary investment objective, the Fund will seek capital appreciation. The fund seeks to achieve its investment objectives by investing, under normal market conditions, across fixed income sectors and securities in seeking to deliver a well-diversified portfolio.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.